Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sumatriptan. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1D known ✓ | P28221 | 7/20 | 1.00 |
| ▸ | HTR1B known ✓ | P28222 | 7/20 | 1.00 |
| ▸ | HTR1A | P08908 | 13/20 | 1.00 |
| ▸ | HTR2C | P28335 | 6/20 | 1.00 |
| ▸ | HTR2A | P28223 | 4/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | HTR5A | P47898 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | HTR1E | P28566 | 1/20 | 1.00 |
| ▸ | HTR1F | P30939 | 1/20 | 1.00 |
| ▸ | HTR3A | P46098 | 1/20 | 1.00 |
| ▸ | SLC47A1 | Q96FL8 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.65 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.65 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.65 |
| ▸ | MPO | P05164 | 1/20 | 0.55 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sumatriptan SCHEMBL1482 | 1.00 | HTR1A (1.00) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL29450235 | 1.00 | HTR1A (1.00) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL1421675 | 0.99 | HTR1A (0.98) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL4916383 | 0.99 | HTR1A (0.98) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL1503483 | 0.96 | HTR1A (0.93) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL29657591 | 0.96 | HTR1A (0.93) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL6688549 | 0.94 | HTR1A (0.89) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL6689001 | 0.93 | HTR1A (0.87) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| SCHEMBL29355619 | 0.93 | HTR1D (0.87) | HTR1AHTR1DHTR1BHTR2CHTR2A | |
| Sumatriptan SCHEMBL2404748 | 0.92 | HTR1A (0.85) | HTR1AHTR1DHTR1BHTR2CHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2978482-B1 | NASAL ADMINISTRATION | OPTINOSE AS (NO) | 2022-05-18 | — | — | EP | disclosed |
| US-11173209-B2 | Compositions for drug administration | AEGIS THERAPEUTICS, LLC (US) | 2021-11-16 | — | — | US | disclosed |
| US-20210121543-A1 | SUTURE LINE ADMINISTRATION TECHNIQUE USING BOTULINUM TOXINS | ALLERGAN INC (US) | 2021-04-29 | — | — | US | disclosed |
| EP-3681584-A1 | IONTOPHORETIC MICRONEEDLE DEVICE | LTS Lohmann Therapie-Systeme AG (DE) | 2020-07-22 | — | — | EP | disclosed |
| US-20200138956-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC | 2020-05-07 | — | — | US | disclosed |
| US-10576156-B2 | Compositions for drug administration | AEGIS THERAPEUTICS, LLC (US) | 2020-03-03 | — | — | US | disclosed |
| WO-2019053051-A1 | LONTOPHORETIC MICRONEEDLE DEVICE | LTS LOHMANN THERAPIE-SYSTEME AG (DE) | 2019-03-21 | — | — | WO | disclosed |
| EP-3368084-A1 | PHARMACEUTICAL COMPOSITIONS FOR TRANSMUCOSAL DELIVERY | Solubest Ltd (IL) | 2018-09-05 | — | — | EP | disclosed |
| US-20180169247-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC | 2018-06-21 | — | — | US | disclosed |
| US-9895444-B2 | Compositions for drug administration | AEGIS THERAPEUTICS, LLC (US) | 2018-02-20 | — | — | US | disclosed |
| EP-2400986-A1 | ENHANCED MIGRAINE TREATMENTS BASED ON GHRELIN MIMETICS | Helsinn Therapeutics (U.S.), Inc. (US) | 2012-01-04 | — | — | EP | disclosed |
| EP-2381773-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | Aegis Therapeutics, LLC (US) | 2011-11-02 | — | — | EP | disclosed |
| CN-1984568-B | Compressed chewing gum tablet | GUMLINK AS | 2011-09-28 | — | — | CN | disclosed |
| WO-2010099522-A1 | ENHANCED MIGRAINE TREATMENTS BASED ON GHRELIN MIMETICS | HELSINN THERAPEUTICS (U.S.), INC. (US) | 2010-09-02 | — | — | WO | disclosed |
| WO-2010075465-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS, LLC (US) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160378-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | AEGIS THERAPEUTICS LLC (US) | 2010-06-24 | — | — | US | disclosed |
| CN-1984568-A | Compressed chewing gum tablet | GUMLINK AS (DK) | 2007-06-20 | — | — | CN | disclosed |
| CN-1315394-C | Low moisture chewing gum | GUMLINK AS (DK) | 2007-05-16 | — | — | CN | disclosed |
| US-20040248846-A1 | Intranasal administration of triptans | NASTECH PHARMACEUTICAL COMPANY INC. | 2004-12-09 | — | — | US | disclosed |
| US-5972916-A | TREATING MIGRAINE PAIN AND THE CLUSTER OF SYMPTOMS CHARACTERISTIC OF MIGRAINE ATTACK, SUCH AS NAUSEA, PHOTOPHOBIA, PHONOPHOBIA AND FUNCTIONAL DISABILITIES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11173209-B2 | Compositions for drug administration | SLC10A1, ABCB11, CSGALNACT1 | HTR1D 4414/4885HTR1B 3113/4885HTR1A 3585/4885 |
| US-20180169247-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | SLC10A1, ABCB11, CSGALNACT1 | HTR1D 4414/4885HTR1B 3113/4885HTR1A 3585/4885 |
| US-20200138956-A1 | COMPOSITIONS FOR DRUG ADMINISTRATION | SLC10A1, ABCB11, CSGALNACT1 | HTR1D 4414/4885HTR1B 3113/4885HTR1A 3585/4885 |
| US-10576156-B2 | Compositions for drug administration | SLC10A1, ABCB11, CSGALNACT1 | HTR1D 4414/4885HTR1B 3113/4885HTR1A 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.